INTRODUCTION
ANCER disease is a major worldwide problem. In the new millennium, rapid progress has been made in the area of a cancer cell, it has become clear that inflammation has an essential role in increased cancer risk. [1, 2] The process of development of cancers may be due to inflammatory cells, in addition to a variety of mediators, like cytokines, chemokines and enzymes. [3] Oxidative stress is an important mechanism in the pathogenesis of many diseases including cancer. The generation of reactive oxygen species (ROS) with consecutive DNA damage is an initial step in carcinogenesis induced by inflammatory processes. [4] ROS is generated either via inflammatory cytokines or via cytochrome P-450 2E1 induction and may lead to lipid peroxidation. Chemokines and pro-inflammatory cytokines as interleukin(IL)-6 and IL-1α can favor the growth of tumor while the treatment with NSAIDS can minimize cancer incidence, [5] so there is a strong relation between cancer and inflammation.
Some of the pro-inflammatory factors such as reactive oxygen species, prostaglandin E2(PGE2) and tumor necrosis factor α (TNF α) are among molecules that play a major role in suppressing inflammation. [6] Nonsteroidal anti-inflammatory drugs (NSAIDS) have inhibitory activity toward cyclooxygenase-1(COX-1) and cyclooxygenase-2 (COX-2). [7] NSAIDS suppress transcription factor NF-kB which regulates COX-2 and inhibits the tumor cell. [8] Quinoline occupies the catalytic split of human DNA repair O 6 -alkylguanine DNA alkyltransferase, by acting as analogs of the O 6 -guanine moiety in the natural substrate, and reaching the catalytic residue Cys145. [9] Furthermore, pyrimidine and fused heterocyclic pyrimidine derivatives show anti-inflammatory and anticancer activities, [10] so the fused ring of quinoline and pyrimidine skeletons
Synthesis of Aryl-2-thioxo-3,6,7,8,9-pentahydro-1H-pyrimido[4,5-b]quinolin-4-ones (3a,b)
A mixture of cyclohexanone (0.01 mol), aryl aldehyde (0.01 mol) and 6-aminothiouracil (0.01 mol) was irradiated in a domestic microwave for 15 min. The reaction mixture was cooled, the precipitate was filtered off, washed with ethanol, dried and crystallized from DMF to produce (3a,b). 
5-(4-FLUOROPHENYL)-2-THIOXO-3,6,7,8,9-PENTAHYDRO-1H-PYRIMIDO[4,5-b]QUINOLIN-4-ONE (3a)
with
Synthesis of 5-Aryl-2-methylthio-6,7,8,9-tetrahydro-3H-pyrimido[4,5-b]quinolin-4-one (4a,b)
To a warm ethanolic potassium hydroxide solution (prepared by dissolving 0.01 mol of potassium hydroxide in 30 mL absolute ethanol) was added compound 3a,b (0.01 mol), the heating was continued for 30 min, the mixture was allowed to cool to room temperature and methyl iodide (0.12 mol) was added. The mixture was stirred under reflux for 3 h, cooled to room temperature, and poured onto cold water (100 mL). The solid precipitated was filtered off, washed with water and dried, crystallized from DMF. in acetone (40 mL) was added. The reaction mixture was stirred at room temperature for 15-24 h (under TLC control). The solvent was evaporated under reduced pressure at 40 °C, and the crude product was filtered off and washed with distilled water to remove KBr formed. The product was dried, and crystallized from the ethanol to produce 5a-d and 7a-d, respectively. 
5-(4-FLUOROPHENYL)-2-METHYLTHIO

Synthesis of Acetylated 2-S-Glycoosides
2-(S-2',3',5'-TRI-O-BENZOYL--D-RIBOFURANOSYL)-5-(4-
FLUOROPHENYL
ANISYL
General Procedure of Deacetylated S-Glycosides of 5-Aryl-6,7,8,9-tetrahydro-3H-pyrimido-[4,5-b]quinolin-4-one (6a-d and 8a-d)
Dry gaseous ammonia was passed through a solution of acetylated compound 5a-d or 7a-d (1.0 mmol) in dry methanol (20 mL) at room temperature for 10 min. The mixture was stirred overnight (followed by TLC). The resulting mixture was then evaporated under reduced pressure to afford a solid residue that was crystallized from ethanol to afford 5-
, as a white powder, respectively.
5-(4-FLUOROPHENYL)-2-S-(-D-RIBOFURANOSYL)-6,7,8,9-TETRAHYDRO-3H-PYRIMIDO[4,5-b]QUINO-LIN-4-ONE (6a)
Yield 52 
5-(4-FLUOROPHENYL)-2-S-(-D-ARABINOFURANOSYL)-6,7,8,9-TETRAHYDRO-3H-PYRIMIDO[4,5-b]QUINOLIN-4-ONE (6c)
5-(4-FLUOROPHENYL)-2-S-(-D-GLUCOPYRANOSYL)-6,7,8,9-TETRAHYDRO-3H-PYRIMIDO[4,5-b]QUINO-LIN-4-ONE (8a)
5-(4-ANISYL)-2-S-(-D-GLUCOPYRANOSYL)-6,7,8,9-TETRAHYDRO-3H-PYRIMIDO[4,5-b]QUINOLIN-4-ONE (8b)
5-(4-ANISYL)-2-S-(-D-GALACTOPYRANOSYL)-6,7,8,9-TETRAHYDRO-3H-PYRIMIDO[4,5-b]-QUINOLIN-4-ONE (8d)
Synthesis of 5-
3-(GLUCOSYL)-5-(4-FLUOROPHENYL)-
Animals
Adult male albino rats (Harlan Sprague-Dawley), weighing 150-180 g, were used for the evaluation of antiinflammatory activity. Animals were fasted for 12 hours before the assay. International principle and local regulations concerning the care of used laboratory animals was taken into account. [23] All animals were obtained from the animal house colony of the National Research Centre, Cairo, Egypt. The animals were acclimatized to the experimental room having temperature 22 ± 1 °C, controlled humidity conditions, and 14 : 10 h light and dark cycle. The rats were fed on autoclaved standard mice food pellets (Hindustan Lever Ltd., New Delhi) and water ad libitum.
Anti-Inflammatory Activity
Carrageenin-induced paw edema test was performed on male albino rats by using the method of Winter et al. [24] The animals were weighed, marked for identification and divided into 14 groups, each group containing 6 animals. 1 % carboxymethyl cellulose (CMC) was selected as vehicle to suspend the standard drug and test compounds. The 1 st group was kept as control and was given the respective volume of vehicle (1 % CMC, oral) only. The 2 nd to 13 th groups were given a 100 mg kg -1 body mass oral dose of test compounds. One hour later, 0.2 mL of 1 % carrageenan suspension in 0.9 % NaCl solution was injected subcutaneously, into the subplantar tissue of the right hind paw of each mouse and the paw volume was measured with a plethysmometer (UGO Basile 7140, model-7141, Biological research apparatus, Italy) . The initial paw volume was measured within 30 s of the injection and remeasured again 1 h, 2 h, 3 h and 4 h after administration of Carrageenan. The last group was administered indomethacin in a dose of 10 mg kg -1 orally as a standard reference. [25] The mean increase in paw volume was compared with that of control group and percent inhibition values were calculated by the formula given below: % anti-inflammatory activity = (Vc -Vt / Vc) × 100. Where Vt represents the paw volume in drug treated animals and Vc represents the paw volume of control group of animals. Some of the synthesized compounds (3a,b), (6a,b), (8a,b),  (9a,b), (11a,b) and (13a,b) were tested for in vitro anticancer activity against three human tumor cell lines, HepG2 (human liver carcinoma), NCI-H460 (non-small cell lung cancer) and MCF-7 (breast adenocarcinoma) by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. [26] HepG2 and NCI-H460 were kindly provided by the National Cancer Institute (Cairo, Egypt) and MCF-7 was obtained from the European Collection of Cell Cultures (Salisbury, UK). They grew as monolayers and were routinely maintained in RPMI-1640 medium supplemented with 5 % heat inactivated FBS, 2 mmol L -1 glutamine and antibiotics (penicillin 100 U mL -1 , streptomycin 100 µg mL -1 ), at 37 °C in a humidified atmosphere containing 5 % CO2. Exponentially growing cells were obtained by plating 1.5 × 10 5 cells mL -1 , followed by 24 h incubation. The effect of the vehicle solvent DMSO on the growth of these cell lines was evaluated by exposing untreated control cells to the maximum concentration (0.5 %) of DMSO used in each assay. The effect of compounds on in vitro growth of human tumor cell lines was evaluated according to the procedure adopted by the national cancer institute (NCI, USA) by using sulforhodamine B as protein binding dye to assess cell growth. [27] Cells growing exponentially in 96-well plates were then exposed for 48 h to five different concentrations of each test compound (5, 12, 25, 50 and 100 µmol L -1 ). After this exposure period, adherent cells were fixed, washed and stained. The bound stain was solubilized and the optical density (absorbance) was measured, and the growth inhibition of 50 % (GI50) was calculated. [28] Doxorubicin was used as a reference compound ( Table 2) .
In vitro
CELL CULTURES
RESULTS AND DISCUSSION
In continuation of our drug research program, and on the basis of the above considerations, original nucleoside analogs directed upon reverse transcriptase still aroused considerable interest. [29] In this study the synthetic pathways depicted in Schemes 1 and 2 outlines the chemistry of the present study. Thus, pyrimido- [4,5-b] quinoline as the starting materials 3a,b are easily prepared following the well established procedure reported in the literature. [12] Treatment of 6-aminothiouracil with cyclohexanone gave the corresponding 1,4-dihydropyridine derivatives as intermediates 1, 2 which in turn gave compounds 3a,b upon microwave irradiation at 90 °C for 20 min in DMF with arylaldehyde (Scheme 1). Compounds 3a,b was found to be useful for the syntheses of the interesting S-glycosides. As a model experiment the alkylation of 4a,b was carried out by the reaction of one equivalent of methyl iodide with the potassium salt of 3a,b (generated in situ by the reaction of 3a,b with alcoholic potassium hydroxide). The structure of the new 2-methylthioquinoline 4a,b was confirmed by all spectroscopic data. The 13 C NMR spectrum as an example revealed that the corresponding signal of the C-2 (C-SCH3) appeared at   159 ppm. The chemical shifts in the 13 C NMR spectrum of the 2-thioxo-(4a) and 2-methylthiopyrimidine in the literature [30] indicated that the site of the alkylation is the sulfur atom rather than the nitrogen atom (Scheme 1).
The synthetic route we used for the preparation of 2-S-(-D-glycopyranosyl / or furanosyl)-pyrimido [4,5-b] protons but showed the multiplet signal supported to the hydroxyl group protons in the region  3.55-3.80 (D2O exchangeable), the signals due to the protons of the sugar moiety at  3.85-5.68. Also, the 13 C NMR spectrum for compound 11d as an example showed eight lines around 22.31-71.23 corresponding to ten sp 3 carbon atoms, thirteen lines around 121.6-157.2 supported to the sp 2 carbon atoms and the absorption signal corresponds to the carbonyl group at 165.6. The anti-inflammatory activity of newly synthesized compounds was evaluated by carrageenan-induced paw edema model in rats using indomethacin as a reference drug. Results are expressed as mean ±S.D. (Table 1) . Differences between control and treatment groups evaluated for statistical significance using one way ANOVA followed by Tukey's test. The test compounds administered 1 h prior to carrageenan injection at a dose of 100 mg kg -1 body wt. caused significant inhibition of paw edema volume. Most of the tested compounds showed good antiinflammatory activity after the 2 nd hour of drug treatment comparable to the standard drug Indomethacin. Compound 6a comprising S-ribofuranozyl moiety was found to be most potent, showing very high activity after 1 st , 2 nd , 3 rd as well as 4 th hour of drug, exhibited activity of 78.6 % in comparison with Indomethacin (92.8 %). Compounds 8a (S-glucopyranozyl) and 13a (1,2,4-triazoloribosyl), in addition to 4-fluorophenyl substitution on pyrimidoquinoline derivatives confer high antiinflammatory activity in the range 58.7-76.5 % compared to Indomethacin. Compound 11a (1,2,4-triazologlucosyl) showed excellent activity (83.4 %), comparable to the standard drug Indomethacin (85.2 %). Compound 3a with pyrimidoquinoline-2-thion, hydrazino derivative of pyrimidoquinoline 11b and 13b exhibited excellent inhibition of paw edema volume. Among the tested compounds, incorporation of electron releasing pmethoxyphenyl on pyrimidoquinoline 3b, 6b, 8b and 9b resulted in a decrease of activity.
The effect of newly synthesized compounds was evaluated through the in vitro growth of three human tumor cell lines representing different tumor types, namely, human liver carcinoma (HepG2), non-small cell lung cancer (NCI-H460) and breast adenocarcinoma (MCF-7), after continuous exposure for 48 h. The results summarized in Table ( 2) showed that most of the tested compounds exhibited significant activity compared to doxorubicin. Compounds 6a (GI50 = 0.01, 0.04 and 0.08 µmol L -1 ), 13a (GI50 = 0.01, 0.03 and 0.06 µmol L -1 ) exhibited higher anticancer activity than that of doxorubicin (GI50 = 0.04, 0.05 and 0.09 µmol L -1 ) against the three tumor cell line, respectively. Such high activity of both compounds is attributed to the insertion of ribofuranosyl moiety at position 2 of compound 3a as in compound 6a, and the presence of more hydroxyl group of ribosyl moiety attached to the triazolopyrimidoquinoline as in compound 13a. In addition to this, the presence of fluorine atom in the Table 1 . Anti-inflammatory activity of tested compounds. 
